公开(公告)号：US20130267518A1

公开(公告)日：2013-10-10

申请号：US13910769

申请日：2013-06-05

Applicant: Novartis AG

Inventor： Kamlesh Jagdis Bala ,  Catherine Leblanc ,  David Andrew Sandham ,  Katherine Louise Turner ,  Simon James Watson ,  Lyndon Nigel Brown ,  Brian Cox

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K45/06

Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.

Abstract translation: 根据本发明，提供游离或盐形式的式（I）化合物，其中R 1，R 2，R 3，R 4，R 5，R 6，Q，W，X，m，n和p如说明书中所述， 制备它们的过程，以及它们作为药物的用途。

公开(公告)号：US09169251B2

公开(公告)日：2015-10-27

申请号：US14316503

申请日：2014-06-26

Applicant: Novartis AG

Inventor： Kamlesh Jagdis Bala ,  Catherine Leblanc ,  David Andrew Sandham ,  Katharine Louise Turner ,  Simon James Watson ,  Lyndon Nigel Brown ,  Brian Cox

IPC: A61K31/437 ,  A61K45/06 ,  C07D471/04

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K45/06

Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.

Abstract translation: 根据本发明，提供游离或盐形式的式（I）化合物，其中R 1，R 2，R 3，R 4，R 5，R 6，Q，W，X，m，n和p如说明书中所述， 制备它们的过程，以及它们作为药物的用途。

公开(公告)号：US20180243297A1

公开(公告)日：2018-08-30

申请号：US15963535

申请日：2018-04-26

Applicant: Novartis AG

Inventor： Benjamin Richard Bellenie ,  Graham Charles Bloomfield ,  Ian Bruce ,  Andrew James Culshaw ,  Edward Charles Hall ,  Gregory John Hollingworth ,  James Neef ,  Matthew Spendiff ,  Simon James Watson

IPC: A61K31/497 ,  C07D413/14 ,  A61K31/5377 ,  C07D405/04 ,  C07D409/14 ,  C07D417/14 ,  C07D401/14 ,  C07D413/04 ,  C07D409/04 ,  C07D403/14 ,  C07D403/04 ,  C07D401/04 ,  C07D405/14 ,  C07D417/04

CPC classification number: A61K31/497 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.

公开(公告)号：US08791256B2

公开(公告)日：2014-07-29

申请号：US13910769

申请日：2013-06-05

Applicant: Novartis AG

Inventor： Kamlesh Jagdis Bala ,  Catherine Leblanc ,  David Andrew Sandham ,  Katharine Louise Turner ,  Simon James Watson ,  Lyndon Nigel Brown ,  Brian Cox

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K45/06

Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.

Abstract translation: 根据本发明，提供游离或盐形式的式（I）化合物，其中R 1，R 2，R 3，R 4，R 5，R 6，Q，W，X，m，n和p如说明书中所述， 制备它们的过程，以及它们作为药物的用途。